“You’re really training your immune system not just to deal better with existing variants, but it actually prepares a broader repertoire to deal with new variants,” Dolsten said. Vaccines also spur T cells that can prevent serious illness if someone does get infected, and Pfizer’s first tests showed, as expected, those don’t seem to be affected by omicron.Īlso, memory cells that can create new and somewhat different antibodies form with each dose. Pfizer’s preliminary lab testing, released Wednesday, hint that might be the case but antibodies aren’t the only layer of defense. infectious disease expert, hopes the big antibody jump triggered by booster doses will compensate. Even if immunity against omicron isn’t as good, Dr. So far, the original vaccines have offered at least some cross-protection against prior variants. Pfizer and Moderna already have successfully brewed experimental doses to match delta and another variant named beta, shots that haven’t been needed but offered valuable practice.
Other manufacturers that make COVID-19 vaccines using different technology, including Johnson & Johnson, also are pursuing possible updates. Moderna is predicting 60 to 90 days to have an omicron-specific candidate ready for testing.
Mikael Dolsten told The Associated Press. Pfizer expects to have an omicron-specific candidate ready for the Food and Drug Administration to consider in March, with some initial batches ready to ship around the same time, chief scientific officer Dr. The Pfizer and Moderna vaccines are fastest to tweak, made with genetic instructions that tell the body to make harmless copies of the spike protein - and that messenger RNA can be swapped to match new mutations.
If vaccines do need tweaking, there’s still another question: Should there be a separate omicron booster or a combination shot? And if it’s a combo, should it target the original strain along with omicron, or the currently dominant delta variant plus omicron? Here’s what we know.ĬOVID-19 vaccines work by triggering production of antibodies that recognize and attack the spike protein that coats the coronavirus, and many are made with new technology flexible enough for easy updating. government’s vaccine advisers wondered why boosters weren’t retooled to target the extra-contagious delta variant - only to have the next scary mutant, omicron, be neither a delta descendant nor a very close cousin. It’s a tough decision - and the virus moves faster than science. A company could apply to market a new formula “but what happens if another company makes another proposal with another variant? We don’t have an agreed strategy.” “This is not trivial,” BioNTech CEO Ugur Sahin, Pfizer’s vaccine partner, said shortly before omicron’s discovery. The World Health Organization has appointed an independent scientific panel to advise on whether the shots need reformulating because of omicron or any other mutant.īut authorities haven’t laid out what would trigger such a drastic step: If vaccine immunity against serious illness drops, or if a new mutant merely spreads faster? and other countries are keeping a close watch. And a booster shot may rev up immunity enough to do both.īetter answers are expected in the coming weeks and regulators in the U.S. The first hints this week were mixed: Preliminary lab tests suggest two Pfizer doses may not prevent an omicron infection but they could protect against severe illness.
It’s too soon to know how vaccines will hold up against omicron. John Wherry of the University of Pennsylvania. Whether it turns out to be a false alarm, it would be really good to know if we can actually do this - get a new vaccine rolled out and be ready,” said immunologist E.
Vaccine makers are racing to update their COVID-19 shots against the newest coronavirus threat even before it’s clear a change is needed, just in case.Įxperts doubt today’s shots will become useless but say it’s critical to see how fast companies could produce a reformulated dose and prove it works - because whatever happens with omicron, this newest mutant won’t be the last.